Engineered immune cells take on childhood cancers in early trial
NCT ID NCT01953900
First seen Jan 30, 2026 · Last updated May 17, 2026 · Updated 19 times
Summary
This early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapies. The approach uses a patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells carrying a protein called GD2. To help these cells last longer in the body, participants also receive a chickenpox vaccine. The main goals are to find a safe dose and understand side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.